2018-11-12T09:26:16-07:00 2017-12-31 870343246 SQUIRE & COMPANY PC 215 S STATE ST STE 850 SALT LAKE CITY UT 841112380 990 2017-01-01 455354811 CROWDCARE FOUNDATION CROW 8019491034 3315 MAYFLOWER DR SUITE 1 LEHI UT 84043 JENNIFER AHLSTROM PRESIDENT 8019491034 2018-11-02 true GREGORY O HYDE P00641196 8015330409 2018-11-12 97.75.179.98 2018-11-12 10:26:16 CS P 91DF67BEE56A6DEEAC0951DC88FC70C0B3CADF07 91DF67BEE56A6DEEAC0951DC88FC70C0B3CADF07 2017 2019-02-21 02:37:17Z JENNIFER AHLSTROM 3315 MAYFLOWER DR 1 LEHI UT 84043 990141 false X WWW.CROWDCARE.ORG X 2012 DE A PATIENT-CENTERED APPROACH TO HEALTHCARE INNOVATION FOR RARE CANCERS AND ORPHAN DISEASES. 6 5 2 4 0 636693 982751 0 -1042 0 191 -61012 635842 921739 310000 80568 0 7659 30349 0 31929 236744 341999 554403 452916 81439 468823 220966 674440 23267 7918 197699 666522 X A PATIENT-CENTERED APPROACH TO HEALTHCARE INNOVATION FOR RARE CANCERS AND ORPHAN DISEASES. false false 249214 27012 PATIENT ADVOCACY (PSA): WITH A PATIENT'S PERSPECTIVE, THE CROWDCARE FOUNDATION SOLVES COMMON PROBLEMS FOR PATIENTS WITH ORPHAN DISEASE USING PRACTICAL AND SIMPLE SOLUTIONS. THE MYELOMA CROWD (WWW.MYELOMACROWD.ORG) AND ALS CROWD (ALSCROWD.ORG) WEBSITES OFFER AGGREGATED INFORMATION AND THE LATEST NEWS AND INFORMATION FOR EACH DISEASE COMMUNITY. ADDITIONALLY WE PROVIDE ONLINE SUPPORT GROUPS FOR EACH COMMUNITY FOR PATIENTS TO SHARE CRITICAL INFORMATION ABOUT THEIR DISEASE. 58534 53556 SUPPORT FOR CLINICAL TRIALS (SCT): THE CROWDCARE FOUNDATION RECOGNIZES THAT LITTLE-KNOWN DISEASES PROVIDE A SIGNIFICANT CHALLENGE: THERE AREN'T THAT MANY PATIENTS TO PARTICIPATE IN CLINICAL RESEARCH. THE CROWDCARE FOUNDATION AIMS TO PROMOTE CLINICAL TRIAL PARTICIPATION TO HELP ACCELERATE THE PACE OF MEDICAL RESEARCH. THE MYELOMA CROWD RADIO AND ALS CROWD RADIO SHOWS INTERVIEW TOP RESEARCHERS AND ENCOURAGE PATIENTS TO JOIN CLINICAL TRIALS IN THEIR RESPECTIVE DISEASE STATES. THESE SHOWS GIVE PATIENTS INSIGHT INTO THE LATEST RESEARCH BEING PERFORMED. ADDITIONALLY, THE MYELOMA CROWD RESEARCH INITIATIVE IS A CROWDSOURCED AND CROWDFUNDING RESEARCH PROJECT TO FIND AND FUND THE BEST RESEARCH FOR HIGH-RISK MYELOMA PATIENTS. THE MCRI IS NOW FUNDING TWO IMMUNOTHERAPY PROJECTS: DR. HERMANN EINSELE AND DR. MICHAEL HUDECEK AT THE UNIVERSITY OF WURZBURG AND DR. IVAN BORRELLO AT JOHNS HOPKINS. ALS CROWD IS DEVELOPING A DATA AGGREGATE SYSTEM FOR ALS PATIENTS TO IDENTIFY KEY DRIVERS AND BIOMARKERS TO BETTER DEFINE THE DISEASE. 49705 DATA SOLUTIONS (DS): THE MYELOMA CROWD LAUNCHED THE HEALTHTREE DATA SOLUTIONS INITIATIVE AS A DECISION TREE SUPPORT TOOL FOR PATIENTS. THIS INITIATIVE WILL SERVE AS BOTH A PATIENT EDUCATION AND RESEARCH TOOL. TODAY THERE ARE A WIDE VARIETY OF AVAILABLE TREATMENT OPTIONS FOR MYELOMA PATIENTS. KNOWING HOW TO BEST STAGE AND TIME THESE OPTIONS IS BOTH AN ART AND SCIENCE. WITH INPUT FROM TOP MYELOMA EXPERTS, THE POSSIBLE TREATMENT COMBINATIONS WILL BE IDENTIFIED AND PRESENTED TO PATIENTS. AS THEY USE THE TOOL, IMPORTANT PATIENT DATA WILL BE GATHERED, HELPING RESEARCHERS IDENTIFY NEW OPPORTUNITIES FOR CLINICAL TRIALS AND BEST PRACTICES. 357453 true true false false false false false false false false true false false false false false false false false false false true false false true false false true false false false false false false false false false false false false false false false false false false false true 6 0 2 true false false false false false false false false false false false false X 6 5 false false true false false false false true true false false true true true true false false false false false X JENNIFER AHLSTROM 8019491034 3315 MAYFLOWER DRIVE 1 LEHI UT 84043 SETH CHRISTENSEN BOARD MEMBER 8.00 X 0 0 0 OWEN LEGARE BOARD MEMBER 2.00 X 0 0 0 ANNE DRENNAN BOARD MEMBER 2.00 X 0 0 0 ADAM BLUM BOARD MEMBER 2.00 X 0 0 0 ALLYSE SHUMWAY SECRETARY TR 30.00 X 24687 0 0 JENNIFER AHLSTROM PRESIDENT 60.00 X 0 0 0 24687 false false false X 74067 908684 450 982751 7325 74067 68402 -61077 OTHER REVENUE 65 65 65 921739 65 X 40568 40568 40000 40000 24687 24687 4277 4277 1385 1385 1682 1682 4995 4995 270302 256749 11973 1580 10730 10730 18946 1016 17930 25764 1959 23805 3748 3748 1937 1937 OTHER FUNDRAISING (PSA) 2050 2050 LIABILITY INSURANCE 793 793 NEWSLETTER 623 623 BUSINESS LICENSE 317 317 112 10 102 452916 357453 63534 31929 213830 669241 9685 4486 7136 5199 220966 674440 23267 7918 23267 7918 X 197699 666522 197699 666522 220966 674440 468823 X false false false X 56060 94515 218003 636693 982751 1988022 56060 94515 218003 636693 982751 1988022 741360 1246662 1988022 7390 0.62710 X 4263 3227 1036 5422 1259 4163 5199 EUROPE IMMUNOTHERAPY PROJ. 40000 WIRE TRANSFER 1 false false false false false false COLUMBUS RUN 29493 24093 5400 5041 317 13466 BARBERSHOP CAR 21540 21540 477 6139 2 30359 28434 1925 8800 2356 31806 81392 74067 7325 13841 3150 51411 68402 -61077 false UNIVERSITY OF IOWA 200 HAWKINS DR IOWA CITY IA 52242 426004813 501C3 11000 MYELOMA RESEARCH INTERFORM 22 S 1400 W CENTERVILLE UT 84014 8671 MYELOMA RESEARCH OHIO STATE UNIVERSITY 660 ACKERMAN RD 6TH FLOOR PO BOX 183112 COLUMBUS OH 432183312 316025986 501C3 15010 MYELOMA RESEARCH 2 1 FORM 990, PAGE 2, PART III, LINE 4B DR. MICHAEL HUDECEK AT THE UNIVERSITY OF WURZBURG AND DR. IVAN BORRELLO AT JOHNS HOPKINS. ALS CROWD IS DEVELOPING A DATA AGGREGATE SYSTEM FOR ALS PATIENTS TO IDENTIFY KEY DRIVERS AND BIOMARKERS TO BETTER DEFINE THE DISEASE. FORM 990, PAGE 6, PART VI, LINE 4 THE CROWDCARE FOUNDATION CHANGED ITS CORPORATE BYLAWS ARTICLE X, SECTION 5, GRANTS ADMINISTRATION, RESTRICTION ON CONTRIBUTIONS. THE UPDATE ALLOWS THE CORPORATION TO ACCEPT CONTRIBUTIONS EARMARKED BY THE DONOR EXCLUSIVELY FOR ALLOCATION TO A FOREIGN PROJECT, BUT ONLY BY THE ADVANCED APPROVAL OF THE BOARD OF DIRECTORS OF THE CHARITABLE ACTIVITY FOR WHICH THE DONATION WAS MADE. FORM 990, PAGE 6, PART VI, LINE 11B A COPY OF THE RETURN IS PROVIDED TO BOARD MEMBERS VIA EMAIL. FORM 990, PAGE 6, PART VI, LINE 12C COVERED ANNUALLY VIA BOARD MEETINGS. FORM 990, PAGE 6, PART VI, LINE 19 CROWDCARE FOUNDATION HAS NOT MADE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, OR FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. FORM 990, PART VIII PART VIII, LINE 8C - THE NET LOSS FROM FUNDRAISING EVENTS ON LINE 8C DOES NOT REFLECT THE CONTRIBUTION REVENUE PORTION OF THE ORGANIZATION'S FUNDRAISER RECEIPTS. THE CONTRIBUTION PORTION IS REPORTED ON LINE 1C AND SHOWN ON LINE 8A. TO SHOW THE TRUE ECONOMIC BENEFIT OF THE FUNDRAISERS CONDUCTED BY THE ORGAINIZATION, THE CONTRIBUTION PORTION REVENUE IS INCLUDED IN THE GROSS RECEIPTS BELOW: GROSS RECEIPTS FROM ALL EVENTS 80,942 FAIR MARKET VALUE OF IN-KIND CONTRIBUTIONS 450 LESS: EXEPENSES OF EVENTS (68,402) NET ECONOMIC BENEFIT FROM FUNDRAISERS 12,990 FORM 990, PART IX, LINE 11G MYELOMA CROWD RADIO (PSA) 4,937 0 0 MYELOMA CROWD RADIO (SCT) 4,937 0 0 ALS CROWD RADIO SHOW (PSA) 609 0 0 OUTSIDE CONTRACT SERVICES 0 10,500 0 MYELOMA CROWD TV 1,180 0 0 MYELOMA CROWD WEBSITE DEVELOP 27,999 0 0 MUSCLES FOR MYELOMA 23,705 0 0 HEALTH TREE (DS) 49,705 0 0 MYELOMA CROWD ROUNDTABLES 137,276 0 0 COMPUTERS 0 1,473 0 SONGS FOR LIFE (PSA) 17 0 0 MYELOMA CROWD MEETUPS (PSA) 6,384 0 0 PAYROLL SERVICES 0 0 1,580 TOTAL 256,749 11,973 1,580